Le Lézard
Classified in: Health
Subjects: RCL, PSF, CFG

Food Recall Warning (Allergen) - President's Choice brand Maple Apple flavour Seasoned Pork Loin Roast recalled due to undeclared mustard


Product photos are available at: https://bit.ly/2FVr4zD

OTTAWA, ON, Sept. 27, 2020 /CNW/ - Loblaw Companies Ltd. is recalling President's Choice brand Maple Apple flavour Seasoned Pork Loin Roast from the marketplace because it contains mustard which is not declared on the label. People with an allergy to mustard should not consume the recalled product described below.

The following product has been sold in Quebec.

Recalled product

Brand

Product

Size

UPC

Codes

President's Choice

Maple Apple flavour Seasoned Pork Loin Roast

730 g

0 60383 20663 5

Best Before 2020 OC 13

What you should do

Check to see if you have the recalled product in your home. Recalled products should be thrown out or returned to the store where they were purchased.

If you have an allergy to mustard, do not consume the recalled product as it may cause a serious or life-threatening reaction.

Background

This recall was triggered by the company. The Canadian Food Inspection Agency (CFIA) is conducting a food safety investigation, which may lead to the recall of other products. If other high-risk products are recalled, the CFIA will notify the public through updated Food Recall Warnings.

The CFIA is verifying that industry is removing the recalled product from the marketplace.

Reactions

There have been no reported reactions associated with the consumption of this product.

SOURCE Canadian Food Inspection Agency (CFIA)


These press releases may also interest you

26 avr 2024
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

26 avr 2024
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

26 avr 2024
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

26 avr 2024
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

26 avr 2024
David J. Dykeman, co-chair of the Life Sciences & Medical...

26 avr 2024
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...



News published on and distributed by: